An RPB researcher has found that the age of immune cells, called macrophages, may be key in determining whether damaging blood vessels will form beneath the retina and contribute to vision loss in age-related macular degeneration. A better understanding of how these macrophages work can provide potential targets for therapies to slow or even reverse vision loss. The findings are reported in the November issue of the Journal of Clinical Investigation. Read the full press release.
Age-related macular degeneration is the leading cause of blindness in the United States in people over the age of 50. It accounts for more than 40 percent of blindness among the elderly in nursing homes, and as baby boomers get older, the problem is expected to grow, with at least 8 million cases predicted by the year 2020.
November 2, 2007
Patricia Ann D’Amore, PhD, MBA, is recognized for ground-breaking contributions to the field of vision research.
RPB funds a new round of researchers and hits a milestone in supporting vision-related breakthroughs.
This ground-breaking research accomplishment will open new doors for research on neurodegenerative diseases like AMD.
RPB grantees provide expert insight on geographic atrophy and dry AMD as part of the "Lunch & Learn" series.
Join RPB and Apellis Pharmaceuticals for a virtual event on Feb. 25 to learn about cutting-edge research into geographic atrophy and dry AMD.
RPB grantees provide expert advice on dry AMD as part of the "Lunch & Learn" series.
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
General Info | Grants | News & Resources |